Generate Biomedicines, Inc. (GENB) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$71.61M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$64.11M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$60.15M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$48.15M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$71.61M | (m) | $6.31M | (m) | $933.00K* | -$57.94M* | (m) | $64.33M | (m) | $53.00K |
| 2026-03-31 | Reported | (m) | -$64.11M | (m) | $7.22M | (m) | $3.78M | -$80.39M | (m) | $57.81M | (m) | $28.00K |
| 2025-06-30 | Reported | (m) | -$60.15M | (m) | $10.13M | (m) | $154.00K* | -$48.75M* | (m) | $59.73M | (m) | $44.00K |
| 2025-03-31 | Reported | (m) | -$48.15M | (m) | $8.82M | (m) | $751.00K | -$53.18M | (m) | $46.83M | (m) | $56.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |